X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (379) 379
hiv infections - drug therapy (305) 305
raltegravir potassium (297) 297
index medicus (272) 272
male (225) 225
female (221) 221
adult (201) 201
raltegravir (178) 178
infectious diseases (172) 172
middle aged (168) 168
pyrrolidinones - adverse effects (159) 159
pyrrolidinones - therapeutic use (138) 138
anti-hiv agents - adverse effects (127) 127
hiv (124) 124
treatment outcome (114) 114
anti-hiv agents - therapeutic use (112) 112
hiv integrase inhibitors - therapeutic use (110) 110
pharmacology & pharmacy (107) 107
hiv integrase inhibitors - adverse effects (103) 103
pyrrolidinones - administration & dosage (103) 103
anti-hiv agents - administration & dosage (97) 97
hiv infections - virology (97) 97
immunology (97) 97
hiv-1 - drug effects (90) 90
viral load (84) 84
drug therapy, combination (80) 80
antiretroviral therapy (79) 79
pharmacokinetics (72) 72
antiviral agents (70) 70
drug therapy (68) 68
hiv infection (68) 68
safety (68) 68
cd4 lymphocyte count (67) 67
drug interactions (66) 66
virology (59) 59
hiv integrase inhibitors - administration & dosage (58) 58
hiv-1 (56) 56
pyrrolidinones - pharmacokinetics (55) 55
efficacy (54) 54
human immunodeficiency virus--hiv (54) 54
microbiology (54) 54
raltegravir potassium - adverse effects (53) 53
aids/hiv (52) 52
young adult (52) 52
dosage and administration (51) 51
raltegravir potassium - therapeutic use (49) 49
infection (48) 48
therapy (48) 48
antiretroviral drugs (46) 46
adolescent (45) 45
rna, viral - blood (44) 44
hiv integrase inhibitors - pharmacokinetics (43) 43
integrase inhibitor (43) 43
drug resistance, viral (42) 42
aids (41) 41
drug administration schedule (41) 41
raltegravir potassium - administration & dosage (41) 41
double-blind (40) 40
protease inhibitors (40) 40
tenofovir (40) 40
hiv infections - complications (39) 39
hiv integrase inhibitors - pharmacology (39) 39
aged (38) 38
hiv protease inhibitors - therapeutic use (38) 38
pyrrolidinones - pharmacology (38) 38
research (38) 38
pyrrolidinones (37) 37
care and treatment (35) 35
combination therapy (35) 35
health aspects (35) 35
integrase inhibitor raltegravir (35) 35
hiv protease inhibitors - adverse effects (34) 34
ritonavir (34) 34
hiv-infected patients (33) 33
analysis (32) 32
mk-0518 (32) 32
viral load - drug effects (32) 32
antiretroviral therapy, highly active (31) 31
emtricitabine (31) 31
integrase (31) 31
internal medicine (31) 31
ritonavir - therapeutic use (31) 31
adenine - analogs & derivatives (30) 30
efavirenz (30) 30
hiv-1 - genetics (30) 30
organic chemicals - therapeutic use (30) 30
treatment-naive patients (30) 30
anti-hiv agents - pharmacokinetics (29) 29
antiretroviral therapy, highly active - adverse effects (29) 29
double-blind method (29) 29
hiv-1 - isolation & purification (29) 29
darunavir (28) 28
highly active antiretroviral therapy (28) 28
medicine (28) 28
retrospective studies (28) 28
treatment-experienced patients (28) 28
antiretroviral therapy, highly active - methods (27) 27
drug resistance (27) 27
reverse transcriptase inhibitors - therapeutic use (27) 27
clinical trials (26) 26
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


AIDS, ISSN 0269-9370, 08/2017, Volume 31, Issue 13, pp. 1853 - 1858
Journal Article
Journal of Infectious Diseases, ISSN 0022-1899, 10/2015, Volume 212, Issue 8, pp. 1241 - 1249
Background. Specific antiretroviral therapy (ART) medications and the severity of human immunodeficiency virus (HIV) disease before treatment contribute to... 
human immunodeficiency virus | bone mineral density | protease inhibitor | inflammation | integrase inhibitor | INTIMA-MEDIA THICKNESS | INFECTIOUS DISEASES | ABACAVIR-LAMIVUDINE | TURNOVER | EMTRICITABINE | MICROBIOLOGY | OSTEOPROTEGERIN | IMMUNOLOGY | HIV-INFECTED ADULTS | PROTEASE INHIBITORS | THERAPY | RECEPTOR ACTIVATOR | Raltegravir Potassium - adverse effects | Humans | Middle Aged | Raltegravir Potassium - therapeutic use | Male | Atazanavir Sulfate - adverse effects | HIV - drug effects | Viral Load | Reverse Transcriptase Inhibitors - adverse effects | Young Adult | Ritonavir - adverse effects | Ritonavir - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Female | Reverse Transcriptase Inhibitors - therapeutic use | Drug Therapy, Combination | HIV Protease Inhibitors - adverse effects | Emtricitabine - adverse effects | Emtricitabine - therapeutic use | Tenofovir - adverse effects | Tenofovir - therapeutic use | Anti-HIV Agents - adverse effects | HIV Protease Inhibitors - therapeutic use | Atazanavir Sulfate - therapeutic use | Bone Density - drug effects | HIV Integrase Inhibitors - adverse effects | HIV Integrase Inhibitors - therapeutic use | HIV Infections - drug therapy | Darunavir - adverse effects | HIV Infections - physiopathology | Darunavir - therapeutic use | Antiviral agents | Care and treatment | Analysis | Bones | Dosage and administration | Inflammation | HIV infection | Density | Risk factors | Major and Brief Reports
Journal Article
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 2015, Volume 61, Issue 5, pp. 809 - 816
Journal Article
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 2017, Volume 64, Issue 11, pp. 1591 - 1596
Background. The long-term effectiveness of human immunodeficiency virus (HIV) treatments containing integrase inhibitors is unknown. Methods. We use... 
Comparative effectiveness | HIV | Cohort study | Mortality | Raltegravir | INFECTIOUS DISEASES | cohort study | EFFICACY | SAFETY | HIV-1 INFECTION ANALYSIS | raltegravir | MARGINAL STRUCTURAL MODELS | MICROBIOLOGY | ANTIRETROVIRAL THERAPY | IMMUNOLOGY | TRIAL | NAIVE PATIENTS | comparative effectiveness | mortality | DOUBLE-BLIND | Raltegravir Potassium - adverse effects | United States - epidemiology | HIV Infections - epidemiology | Humans | Middle Aged | Raltegravir Potassium - administration & dosage | Raltegravir Potassium - therapeutic use | Male | RNA, Viral - blood | Tenofovir - administration & dosage | Reverse Transcriptase Inhibitors - administration & dosage | Anti-HIV Agents - administration & dosage | Reverse Transcriptase Inhibitors - adverse effects | Young Adult | Adult | Anti-HIV Agents - therapeutic use | Female | HIV Infections - mortality | Reverse Transcriptase Inhibitors - therapeutic use | Tenofovir - adverse effects | Benzoxazines - administration & dosage | Tenofovir - therapeutic use | HIV-1 - drug effects | Anti-HIV Agents - adverse effects | Benzoxazines - adverse effects | CD4 Lymphocyte Count | Acquired Immunodeficiency Syndrome - drug therapy | Benzoxazines - therapeutic use | HIV Integrase Inhibitors - therapeutic use | Acquired Immunodeficiency Syndrome - epidemiology | Acquired Immunodeficiency Syndrome - mortality | HIV Infections - drug therapy | Viral Load - drug effects | Cohort Studies | HIV patients | Care and treatment | Dosage and administration | Efavirenz | HIV infection | Major
Journal Article
Journal of Pharmacy and Pharmacology, ISSN 0022-3573, 11/2016, Volume 68, Issue 11, pp. 1359 - 1365
Objectives Raltegravir is a human immunodeficiency virus (HIV)‐1 integrase strand transfer inhibitor currently marketed at a dose of 400 mg twice daily (BID).... 
interaction | pharmacokinetics | calcium carbonate | once‐daily | aluminium and magnesium hydroxide | once-daily | ACID-REDUCING AGENTS | THERAPY | VOLUNTEERS | PHARMACOLOGY & PHARMACY | HIV-INTEGRASE INHIBITOR | Raltegravir Potassium - adverse effects | Area Under Curve | Magnesium - administration & dosage | Humans | Middle Aged | Raltegravir Potassium - administration & dosage | Male | Metabolic Clearance Rate | Aluminum Hydroxide - administration & dosage | HIV Integrase Inhibitors - administration & dosage | Drug Interactions | Polypharmacy | Antacids - adverse effects | HIV Infections - diagnosis | Adult | Female | Calcium Carbonate - administration & dosage | Magnesium - adverse effects | Raltegravir Potassium - pharmacokinetics | Drug Administration Schedule | Administration, Oral | HIV Infections - virology | HIV Integrase Inhibitors - pharmacokinetics | Magnesium Hydroxide - adverse effects | Calcium Carbonate - adverse effects | Aluminum Hydroxide - adverse effects | Magnesium Hydroxide - administration & dosage | HIV Integrase Inhibitors - adverse effects | Raltegravir Potassium - blood | HIV Infections - drug therapy | HIV Integrase Inhibitors - blood | Antacids - administration & dosage | Drug Combinations | Urine | Antiviral agents | Analysis | Electrocardiogram | Calcium carbonate | Electrocardiography | Magnesium hydroxide | HIV (Viruses) | Human immunodeficiency virus--HIV | Antacids | Magnesium
Journal Article
European Journal of Clinical Microbiology & Infectious Diseases, ISSN 0934-9723, 3/2019, Volume 38, Issue 3, pp. 423 - 426
Journal Article
PloS one, ISSN 1932-6203, 2018, Volume 13, Issue 6, pp. e0198768 - e0198768
Background Long-term combination antiretroviral therapy often results in toxicity/tolerability problems, which are one of the main reasons for switching... 
TREATMENT-NAIVE | SAFETY | MULTIDISCIPLINARY SCIENCES | NON-INFERIORITY TRIAL | ANTIRETROVIRAL THERAPY | OPEN-LABEL | DOLUTEGRAVIR | TOXICITY | TENOFOVIR | BOOSTED PROTEASE INHIBITOR | HIV-INFECTED PATIENTS | HIV-1 | Raltegravir Potassium - adverse effects | Follow-Up Studies | Anti-HIV Agents - adverse effects | Humans | Middle Aged | Raltegravir Potassium - therapeutic use | Male | Treatment Outcome | Lamivudine - adverse effects | Lamivudine - therapeutic use | Anti-HIV Agents - therapeutic use | Female | HIV Infections - drug therapy | Dideoxynucleosides - adverse effects | Dideoxynucleosides - therapeutic use | Retrospective Studies | Drug Therapy, Combination | Drug Combinations | Treatment outcome | Analysis | Abacavir | Lamivudine | Dosage and administration | Drug therapy | Comparative analysis | HIV infection | Raltegravir | Slopes | Antiretroviral drugs | Toxicity | Medical services | Clinical trials | Population studies | Infections | FDA approval | Males | Ribonucleic acid--RNA | Medical diagnosis | Patients | Antiretroviral therapy | Switching | CD4 antigen | Acquired immune deficiency syndrome--AIDS | Antiretroviral agents | Safety engineering | Human immunodeficiency virus--HIV | Clinical medicine | Failure | Index Medicus | RNA | Acquired immune deficiency syndrome | Ribonucleic acid | AIDS | HIV | Human immunodeficiency virus
Journal Article
PLoS ONE, ISSN 1932-6203, 02/2015, Volume 10, Issue 2, p. e0118228
Objective To determine the durability over 96 weeks of safety and efficacy of lopinavir/ritonavir (LPV/r) and raltegravir (RAL) which was demonstrated to have... 
PROTEASE INHIBITOR | METAANALYSIS | EFFICACY | SAFETY | MULTIDISCIPLINARY SCIENCES | CLINICAL-TRIALS | DISEASE | ADULTS | ANTIRETROVIRAL THERAPY | TENOFOVIR/EMTRICITABINE | HIV Protease Inhibitors - adverse effects | HIV-1 | Raltegravir Potassium - adverse effects | Ritonavir - administration & dosage | Humans | Raltegravir Potassium - administration & dosage | Raltegravir Potassium - therapeutic use | Male | HIV Protease Inhibitors - administration & dosage | Secondary Care | HIV Integrase Inhibitors - administration & dosage | HIV Protease Inhibitors - therapeutic use | Ritonavir - adverse effects | HIV Integrase Inhibitors - adverse effects | HIV Integrase Inhibitors - therapeutic use | Lopinavir - administration & dosage | Ritonavir - therapeutic use | Adult | HIV Infections - drug therapy | Lopinavir - therapeutic use | Drug Therapy, Combination | Lopinavir - adverse effects | Medical research | Low density lipoproteins | HIV (Viruses) | Blood cholesterol | Protease inhibitors | Proteases | Nucleosides | Medicine, Experimental | DNA polymerases | Drug therapy | Health aspects | HIV infection | Trans fatty acids | Lipoproteins (low density) | Therapy | RNA-directed DNA polymerase | Ritonavir | Cardiovascular disease | Randomization | Motivation | Acquired immune deficiency syndrome--AIDS | Lymphocytes | Safety engineering | Human immunodeficiency virus--HIV | Hemoglobin | Safety | Lipoproteins (high density) | Integrase | Antiretroviral drugs | Effectiveness | Hematology | Lopinavir | Durability | Proteinase inhibitors | Ribonucleic acid--RNA | Cholesterol | Adults | RNA | Acquired immune deficiency syndrome | Ribonucleic acid | AIDS | HIV | Human immunodeficiency virus
Journal Article